DE202016008692U1 - Prostata-Antigen-Standards und deren Verwendung - Google Patents

Prostata-Antigen-Standards und deren Verwendung Download PDF

Info

Publication number
DE202016008692U1
DE202016008692U1 DE202016008692.9U DE202016008692U DE202016008692U1 DE 202016008692 U1 DE202016008692 U1 DE 202016008692U1 DE 202016008692 U DE202016008692 U DE 202016008692U DE 202016008692 U1 DE202016008692 U1 DE 202016008692U1
Authority
DE
Germany
Prior art keywords
prostate
antigen
titer
antigens
standards
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE202016008692.9U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OPKO Diagnostics LLC
Original Assignee
OPKO Diagnostics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OPKO Diagnostics LLC filed Critical OPKO Diagnostics LLC
Publication of DE202016008692U1 publication Critical patent/DE202016008692U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DE202016008692.9U 2015-03-27 2016-03-25 Prostata-Antigen-Standards und deren Verwendung Expired - Lifetime DE202016008692U1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562139365P 2015-03-27 2015-03-27
US62/139,365 2015-03-27

Publications (1)

Publication Number Publication Date
DE202016008692U1 true DE202016008692U1 (de) 2019-02-13

Family

ID=56975150

Family Applications (1)

Application Number Title Priority Date Filing Date
DE202016008692.9U Expired - Lifetime DE202016008692U1 (de) 2015-03-27 2016-03-25 Prostata-Antigen-Standards und deren Verwendung

Country Status (15)

Country Link
US (2) US11921115B2 (https=)
EP (2) EP3253800B1 (https=)
JP (1) JP6749337B2 (https=)
CN (1) CN107406510B (https=)
DE (1) DE202016008692U1 (https=)
DK (1) DK3253800T3 (https=)
ES (1) ES2867798T3 (https=)
HU (1) HUE055020T2 (https=)
IL (1) IL254412B (https=)
MX (2) MX392040B (https=)
PL (1) PL3253800T3 (https=)
PT (1) PT3253800T (https=)
TW (1) TWI698639B (https=)
UA (1) UA124522C2 (https=)
WO (1) WO2016160545A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152417B1 (en) 2007-05-04 2018-07-11 Opko Diagnostics, LLC Device and method for analyses in microfluidic systems
ES2695039T3 (es) 2009-02-02 2018-12-28 Opko Diagnostics, Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
TWI596494B (zh) 2012-03-05 2017-08-21 Ｏｐｋｏ診斷法有限責任公司 預測前列腺癌風險及前列腺腺體體積之方法及裝置
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
KR102505543B1 (ko) 2014-03-28 2023-03-02 옵코 다이어그노스틱스, 엘엘씨 전립선암 진단에 관한 조성물 및 방법
PT3253800T (pt) 2015-03-27 2021-04-28 Opko Diagnostics Llc Padrões de antigénio da próstata e suas utilizações
DE102015105979A1 (de) 2015-04-20 2016-10-20 Mankiewicz Gebr. & Co. Gmbh & Co. Kg Verbesserte Beschichtungssysteme, deren Verwendung zur Beschichtung von Bauteilen sowie damit beschichtete Bauteile für Windkraftanlagen
CA3005084A1 (en) 2015-12-11 2017-06-15 Opko Diagnostics, Llc Fluidic systems involving incubation of samples and/or reagents
JP6956719B2 (ja) 2015-12-29 2021-11-02 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏ Ｄｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ 流体の収集のための物品
US12313834B2 (en) 2017-06-15 2025-05-27 Shenzhen Prs Limited Paraffin shield coating for microscope slide
CN110753846B (zh) * 2017-06-15 2024-03-26 深圳市诺高实验器材有限公司 免疫组织化学抗原成像标尺外推方法
US11662564B2 (en) 2017-06-15 2023-05-30 Shenzhen Prs Limited Paraffin shield coating for microscope slide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672480A (en) 1993-12-29 1997-09-30 Abbott Laboratories Immunoassays for prostate specific antigen
US5939533A (en) 1990-07-23 1999-08-17 Lilja; Hans Assay of free and complexed prostate-specific antigen (PSA)
US7872104B2 (en) 2000-09-27 2011-01-18 Arctic Partners Oy Ab Antibody, immunoassay and method for prostate cancer detection

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
DE69433688T2 (de) 1993-10-28 2005-04-28 I-Stat Corp. Vorrichtung zur abnahme und einleitung von flüssigkeitsproben
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US6207369B1 (en) 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
JPH11510601A (ja) 1995-08-03 1999-09-14 アクゾ・ノベル・エヌ・ベー 診断装置
JP3645023B2 (ja) * 1996-01-09 2005-05-11 富士写真フイルム株式会社 試料分析方法、検量線の作成方法及びそれを用いる分析装置
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
CA2360073C (en) 1999-01-28 2011-01-18 Gen-Probe Incorporated Probes and primers for detecting prostate specific antigen (psa) in a biological sample
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
EP1328342A4 (en) 2000-10-10 2006-03-15 Aviva Biosciences Corp INTEGRATED BIOCHIP SYSTEM FOR SAMPLE PREPARATION AND ANALYSIS
JP2004536278A (ja) 2000-11-20 2004-12-02 イースタン・ヴァージニア・メディカル・スクール 前立腺特異的膜抗原、その他の前立腺マーカーの定量的検出方法及び装置
WO2003029427A2 (en) 2001-10-03 2003-04-10 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
US7258837B2 (en) 2001-12-05 2007-08-21 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
AU2003242389A1 (en) 2002-05-28 2003-12-12 Jokoh Co., Ltd Immunological chromatograph method test slip reading/quantitative determination device
NZ562192A (en) 2002-08-06 2009-07-31 Ciphergen Biosystems Inc Use of biomarkers for detecting ovarian cancer
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
US20050118061A1 (en) 2003-11-28 2005-06-02 Sysmex Corporation Analyzer, assay cartridge and analyzing method
WO2005056186A1 (en) 2003-12-10 2005-06-23 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A modular biochip assembly
US7736890B2 (en) 2003-12-31 2010-06-15 President And Fellows Of Harvard College Assay device and method
JP4698613B2 (ja) 2004-01-26 2011-06-08 プレジデント アンド フェロウズ オブ ハーバード カレッジ 流体送達のシステムおよび方法
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
CA2564208A1 (en) 2004-05-11 2005-11-24 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
MX2007001357A (es) 2004-08-02 2009-08-07 Childrens Medical Center Biomarcadores de plaquetas para cancer.
WO2006034032A2 (en) 2004-09-17 2006-03-30 The Johns Hopkins University Biomarkers for breast cancer
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122312A2 (en) 2005-05-11 2006-11-16 The Trustees Of The University Of Pennsylvania Methods of testing using a microfluidic cassette
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
CN101454331A (zh) 2006-03-24 2009-06-10 菲诺梅诺米发现公司 有效用于诊断前列腺癌的生物标记，及其方法
JP2009540852A (ja) 2006-07-03 2009-11-26 エグゾニ・テラピューティック・ソシエテ・アノニム 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
CN101588815B (zh) 2006-12-22 2013-10-23 法蒂亚公司 新前列腺激肽释放酶过敏原
EP2152417B1 (en) 2007-05-04 2018-07-11 Opko Diagnostics, LLC Device and method for analyses in microfluidic systems
AU2008251877A1 (en) 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断前列腺癌试剂盒及其制备方法和检测方法
US20090087860A1 (en) 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离前列腺特异性抗原化学发光免疫分析测定试剂盒及其制备方法
CN101861522B (zh) 2007-10-22 2014-05-14 圣文森特医院悉尼有限公司 预后方法
US20090226912A1 (en) 2007-12-21 2009-09-10 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
CA2724433A1 (en) 2008-05-14 2009-11-19 Eth Zuerich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
KR20110086074A (ko) 2008-10-20 2011-07-27 리포사이언스, 인크. 지질단백질 인슐린 저항성 지표 및 이와 관련된 방법, 시스템 및 이를 생성하기 위한 컴퓨터 프로그램
CA2745961A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2010080115A2 (en) 2008-12-18 2010-07-15 Claros Diagnostics, Inc. Improved reagent storage in microfluidic systems and related articles and methods
WO2010075446A1 (en) 2008-12-23 2010-07-01 Soar Biodynamics, Ltd. Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
ES2695039T3 (es) 2009-02-02 2018-12-28 Opko Diagnostics, Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
SG10201401722XA (en) 2009-05-01 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy
US20120122243A1 (en) 2009-06-04 2012-05-17 Charite Universitatsmedizin Berlin Means and method and means for diagnosing prostate carcinomas
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
BR112012026366B1 (pt) 2010-04-16 2020-05-05 Opko Diagnostics, Llc analisador de amostras microfluídicas e método para analisar uma amostra microfluídica
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US9594086B2 (en) 2011-03-22 2017-03-14 The Johns Hopkins University Biomarkers for aggressive prostate cancer
US20140227720A1 (en) 2011-06-09 2014-08-14 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
JP6072686B2 (ja) 2011-07-21 2017-02-01 和光純薬工業株式会社 血漿中アミノ酸分析用標準液
KR102362358B1 (ko) 2011-10-28 2022-02-15 프레닥스 에이비 치료제 및 이의 용도
WO2013106778A2 (en) * 2012-01-13 2013-07-18 Iris International, Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
TWI596494B (zh) 2012-03-05 2017-08-21 Ｏｐｋｏ診斷法有限責任公司 預測前列腺癌風險及前列腺腺體體積之方法及裝置
EP2850432A2 (en) 2012-05-16 2015-03-25 Phadia AB Method for indicating the presence or non-presence of prostate cancer
NZ703411A (en) 2012-06-27 2017-09-29 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
CN102818892B (zh) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种前列腺特异性抗原检测试剂盒及其制备方法
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
EP2922970B1 (en) 2012-11-20 2018-08-08 Phadia AB Prognostic method for individuals with prostate cancer
US10431326B2 (en) 2012-11-20 2019-10-01 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer
HUE043875T2 (hu) 2013-11-19 2019-09-30 Fredax Ab Humanizált, kallikrein-2 elleni antitest
FI3117216T3 (fi) 2014-03-11 2023-04-27 Phadia Ab Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi
KR102505543B1 (ko) 2014-03-28 2023-03-02 옵코 다이어그노스틱스, 엘엘씨 전립선암 진단에 관한 조성물 및 방법
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
US10217619B2 (en) 2015-03-12 2019-02-26 Thermo Finnigan Llc Methods for data-dependent mass spectrometry of mixed intact protein analytes
PT3253800T (pt) 2015-03-27 2021-04-28 Opko Diagnostics Llc Padrões de antigénio da próstata e suas utilizações
KR102527446B1 (ko) 2015-04-29 2023-05-02 옵코 다이어그노스틱스, 엘엘씨 전립선암의 적극적 감시를 위한 조성물 및 방법
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
EP3794354A4 (en) 2018-05-16 2022-01-12 Opko Diagnostics, LLC METHODS OF DETECTING PROSTATE CANCER ASSOCIATED WITH NEGATIVE RESULTS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939533A (en) 1990-07-23 1999-08-17 Lilja; Hans Assay of free and complexed prostate-specific antigen (PSA)
US5672480A (en) 1993-12-29 1997-09-30 Abbott Laboratories Immunoassays for prostate specific antigen
US7872104B2 (en) 2000-09-27 2011-01-18 Arctic Partners Oy Ab Antibody, immunoassay and method for prostate cancer detection

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
epitopes of prostate specific antigen (PS A) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling. Protein Science (1998), 7:259-269
Lilja et al. 1991. Prostate-Specific Antigen in Serum
Nurmikko et al. 2000. Production and Characterization of Novel Anti-Prostate-specific Antigen (PSA) Monoclonal Antibodies That Do Not Detect Internally Cleaved Lys145-Lys146 Inactive PSA. Clin Chem
Occurs Predominantly in Complex with alpha-1-Antichymotrypsin. Clin Chem. 37(9), 1618-1625. Piironen, et al. Determination and analysis of antigenic

Also Published As

Publication number Publication date
US20240159758A1 (en) 2024-05-16
EP3253800A1 (en) 2017-12-13
EP3318878A2 (en) 2018-05-09
EP3253800A4 (en) 2018-11-07
EP3253800B1 (en) 2021-03-03
HUE055020T2 (hu) 2021-11-29
CN107406510B (zh) 2022-02-18
EP3318878A3 (en) 2018-07-11
JP6749337B2 (ja) 2020-09-02
TWI698639B (zh) 2020-07-11
TW201643429A (zh) 2016-12-16
US12510543B2 (en) 2025-12-30
IL254412B (en) 2021-01-31
WO2016160545A1 (en) 2016-10-06
PT3253800T (pt) 2021-04-28
ES2867798T3 (es) 2021-10-20
CA2979559A1 (en) 2016-10-06
DK3253800T3 (da) 2021-05-31
UA124522C2 (uk) 2021-10-05
PL3253800T3 (pl) 2021-08-23
US20170370938A9 (en) 2017-12-28
MX2017012320A (es) 2018-01-18
CN107406510A (zh) 2017-11-28
MX2022002138A (es) 2022-03-17
JP2018511055A (ja) 2018-04-19
US20160282349A1 (en) 2016-09-29
MX392040B (es) 2025-03-21
US11921115B2 (en) 2024-03-05
IL254412A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
DE202016008692U1 (de) Prostata-Antigen-Standards und deren Verwendung
Dietel et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists
DE202015009668U1 (de) Zusammensetzungen zur Diagnose von Prostatakrebs
Sun et al. Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer
Kiernan et al. Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct
DE202010018327U1 (de) Überlebensprognosetest
DE202016008673U1 (de) Zusammensetzungen zur aktiven Überwachung von Prostatakrebs
Akar et al. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis
CN108613977B (zh) 一种n末端脑钠肽前体检测试剂盒
Grasko et al. A diagnostic conundrum: heterophilic antibody interference in an adrenocorticotropic hormone immunoassay not detectable using a proprietary heterophile blocking reagent
Navarro et al. Urinary sediment microscopy and correlations with kidney biopsy: red flags not to be missed
DE69808895T2 (de) Leistungssteigerung von bindungsassays mit verwendung mehr als einer markierungsmittel
Update Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Zhang et al. KRT15 in early breast cancer screening and correlation with HER2 positivity, pathological grade and N stage
Singh et al. Protein Biomarkers: Discovery and Applications in Clinical Diagnostics
Yang et al. Performance verification of a new domestic chemiluminescence detection system
EP2812694A2 (en) Assays and methods for the diagnosis of ovarian cancer
Shah et al. Single-day HER2neu amplification assessment using chip-based digital PCR in formalin-fixed paraffin-embedded breast carcinoma tissue
Khoshkhui et al. Evaluating the tissue expression of thyroid peroxidase in chronic spontaneous urticaria patients
CA2979559C (en) Prostate antigen standards and uses thereof
Palanisamy et al. Urinary Biomarkers for Non-Invasive Diagnosis of Acute Interstitial Nephritis
Keremu et al. Analysis of independent risk factors and construction of a predictive model for thyroid dysfunction in early pregnancy
Dendooven et al. Belgian recommendations for tissue diagnosis of amyloidosis
Pettersson Pablo et al. High levels of hemolysis do not affect measurement of PAPP-A, β-HCG and TRAb on BRAHMS KRYPTOR compact plus
Hempenius et al. Interassay Comparison With Digital Image Analysis of Four Routine HER2 Immunohistochemistry Assays in Primary Breast Cancer and Its Metastasis

Legal Events

Date Code Title Description
R207 Utility model specification
R150 Utility model maintained after payment of first maintenance fee after three years
R151 Utility model maintained after payment of second maintenance fee after six years
R152 Utility model maintained after payment of third maintenance fee after eight years
R079 Amendment of ipc main class

Free format text: PREVIOUS MAIN CLASS: G01N0033574000

Ipc: G01N0033575000

R071 Expiry of right